Cancer is associated with an overall seven fold increased risk of thrombosis.  The main mechanism by which platelet thrombi promote cancer, is by wrapping around circulating tumor cells and protecting them while in circulation and then promoting their attachment on the blood vessel walls of the capillary. Once attached, the tumor cells can then divide and grow to form a metastatic tumor. Since metastasis is the main cause of mortality in cancer, Verseon's thrombin inhibitors can block metastasis by blocking platelet thrombus formation.

Verseon has developed anti-thrombotics that exert their inhibitory effect on thrombin via a novel mechanism of action. In fact, Verseon’s compounds are the first small molecules shown to inhibit thrombin via a novel mechanism of action. This novel mechanism of action promises novel pharmacology and reduced bleeding liability necessary for oncology indications

Verseon's novel DTIs promise an entirely new method of treating many types of solid tumor cancers such as breast, prostate, and others.